Arthur M. Cohen & Associates’s Sage Therapeutics SAGE Stock Holding History

Arthur M. Cohen & Associates’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,690	Closed	-$201K	–	144
2021 Q1	$201K	Hold	2,690	–	–	0.05%	137
2020 Q4	$233K	Buy	+2,690	New	+$198K	0.05%	134
2020 Q1	–	Sell	-2,970	Closed	-$214K	–	120
2019 Q4	$214K	Sell	2,970 -726	-20%	-$89.3K	0.07%	121
2019 Q3	$518	Hold	3,696	–	–	0.15%	73
2019 Q2	$677K	Sell	3,696 -4,585	-55%	-$782K	0.23%	58
2019 Q1	$1.32M	Hold	8,281	–	–	0.47%	34
2018 Q4	$793	Hold	8,281	–	–	0.25%	49
2018 Q3	$1.17K	Hold	8,281	–	–	0.36%	40
2018 Q2	$1.3M	Hold	8,281	–	–	0.49%	35
2018 Q1	$1.03M	Hold	8,281	–	–	0.39%	44
2017 Q4	$793	Buy	+8,281	New	+$803K	0.22%	48
2017 Q2	$665K	Hold	8,281	–	–	0.26%	60
2017 Q1	$589K	Hold	8,281	–	–	0.26%	57
2016 Q4	$423K	Buy	+8,281	New	+$390K	0.22%	60
2014 Q3	$589K	Buy	+8,281	New	+$240K	0.27%	64

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arthur M. Cohen & Associates's SAGE Position: Q2 2021 in Review

Arthur M. Cohen & Associates sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 2,690 shares — an estimated $201K sold.

Arthur M. Cohen & Associates first reported a position in SAGE in Q3 2014 and held it in 15 quarters. The position peaked at $1.32M in Q1 2019. 257 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

Arthur M. Cohen & Associates reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
Arthur M. Cohen & Associates sold 2,690 Sage Therapeutics shares in Q2 2021, an estimated $201K.
Arthur M. Cohen & Associates first reported a position in Sage Therapeutics in Q3 2014 and held it in 15 quarters.
Arthur M. Cohen & Associates's Sage Therapeutics position peaked at $1.32M in Q1 2019.
257 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Arthur M. Cohen & Associates's 13F filing for Q2 2021, filed 27 Jul 2021.